CIK 0001817241 · <br>Emerging growth company
Artiva Biotherapeutics, Inc.
Sign in to watch- Ticker
- ARTV
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 863614316
- Phone
- (858) 267-4467
- Business address
- 5505 MOREHOUSE DRIVE, SAN DIEGO, CA, 92121
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,341,159
- in 16 filings, $529K under 10b5-1 plans
Net −$2,341,159. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-07-22 | GC Corp. 10% owner | Conversion · Series B Preferred Stock | −330,095 | 0 | ||
| 2024-07-22 | GC Corp. 10% owner | Conversion · Series A Preferred Stock | −292,791 | 0 | ||
| 2024-07-22 | GC Corp. 10% owner | Conversion · Series B Preferred Stock | −62,181 | 0 | ||
| 2024-07-22 | Huh Yong-Jun Director | Conversion | +667,185 | 1,016,022 | ||
| 2024-07-22 | Huh Yong-Jun Director | Conversion | +330,095 | 1,346,117 | ||
| 2024-07-22 | Huh Yong-Jun Director | Other acquisition | +294,117 | $10.20 | $3.0M | 1,640,234 |
| 2024-07-22 | Huh Yong-Jun Director | Purchase | +1,666,666 | $12.00 | $20.0M | 3,306,900 |
| 2024-07-22 | Huh Yong-Jun Director | Conversion | +292,791 | 525,349 | ||
| 2024-07-22 | Huh Yong-Jun Director | Conversion | +62,181 | 587,530 | ||
| 2024-07-22 | Huh Yong-Jun Director | Other acquisition | +256,316 | $10.20 | $2.6M | 843,846 |
| 2024-07-22 | Huh Yong-Jun Director | Purchase | +416,666 | $12.00 | $5.0M | 1,260,512 |
| 2024-07-22 | Huh Yong-Jun Director | Conversion · Series A Preferred Stock | −667,185 | 0 | ||
| 2024-07-22 | Huh Yong-Jun Director | Conversion · Series B Preferred Stock | −330,095 | 0 | ||
| 2024-07-22 | Huh Yong-Jun Director | Conversion · Series A Preferred Stock | −292,791 | 0 | ||
| 2024-07-22 | Huh Yong-Jun Director | Conversion · Series B Preferred Stock | −62,181 | 0 | ||
| 2024-07-22 | Aslan Fred President and CEO | Grant or award | +228,905 | 228,905 | ||
| 2024-07-22 | venBio Global Strategic Fund III, L.P. 10% owner | Conversion | +843,592 | 843,592 | ||
| 2024-07-22 | venBio Global Strategic Fund III, L.P. 10% owner | Conversion | +214,692 | 1,058,284 | ||
| 2024-07-22 | venBio Global Strategic Fund III, L.P. 10% owner | Other acquisition | +461,687 | 1,519,971 | ||
| 2024-07-22 | venBio Global Strategic Fund III, L.P. 10% owner | Purchase | +416,666 | $12.00 | $5.0M | 1,936,637 |
Page 10 of 11 · 203 trades